Otsuka Holdings Co., Ltd. (OTSKY)
USD 27.55
(-0.4%)
USD 27.55
(-0.4%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 246.95 Billion JPY | 24.08% |
| 2022 | 279.82 Billion JPY | 20.97% |
| 2021 | 231.43 Billion JPY | -15.58% |
| 2020 | 291.03 Billion JPY | 13.91% |
| 2019 | 256.7 Billion JPY | 52.86% |
| 2018 | 133.14 Billion JPY | 3.36% |
| 2017 | 147.16 Billion JPY | -9.7% |
| 2016 | 145.29 Billion JPY | -18.83% |
| 2015 | 220.62 Billion JPY | -12.94% |
| 2014 | 267.99 Billion JPY | 17.2% |
| 2013 | 228.67 Billion JPY | -37.05% |
| 2012 | 212.65 Billion JPY | 9.42% |
| 2011 | 189.7 Billion JPY | 3.78% |
| 2010 | 170.17 Billion JPY | 13.32% |
| 2009 | 149.72 Billion JPY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 140.8 Billion JPY | -34.96% |
| 2024 Q1 | 107.64 Billion JPY | 373.51% |
| 2023 Q4 | 78.33 Billion JPY | -38.99% |
| 2023 Q1 | 103.68 Billion JPY | 61.16% |
| 2023 Q2 | 112.77 Billion JPY | 8.76% |
| 2023 Q3 | 128.39 Billion JPY | 13.85% |
| 2023 FY | - JPY | 24.08% |
| 2022 Q3 | 85.06 Billion JPY | -2.29% |
| 2022 Q4 | 64.34 Billion JPY | -24.36% |
| 2022 FY | - JPY | 20.97% |
| 2022 Q1 | 77.97 Billion JPY | 235.04% |
| 2022 Q2 | 87.05 Billion JPY | 11.64% |
| 2021 FY | - JPY | -15.58% |
| 2021 Q3 | 73.97 Billion JPY | -11.19% |
| 2021 Q4 | 23.27 Billion JPY | -68.54% |
| 2021 Q2 | 83.29 Billion JPY | 4.18% |
| 2021 Q1 | 79.94 Billion JPY | 60.72% |
| 2020 Q3 | 98.75 Billion JPY | 16.58% |
| 2020 Q2 | 84.7 Billion JPY | 13.21% |
| 2020 FY | - JPY | 13.91% |
| 2020 Q1 | 74.82 Billion JPY | 34.44% |
| 2020 Q4 | 49.74 Billion JPY | -49.63% |
| 2019 Q3 | 78.5 Billion JPY | -7.73% |
| 2019 FY | - JPY | 52.86% |
| 2019 Q4 | 55.65 Billion JPY | -29.1% |
| 2019 Q2 | 85.07 Billion JPY | 64.84% |
| 2019 Q1 | 51.61 Billion JPY | 79.58% |
| 2018 Q3 | 34.08 Billion JPY | -47.64% |
| 2018 Q2 | 65.1 Billion JPY | 26.53% |
| 2018 Q4 | 28.74 Billion JPY | -15.68% |
| 2018 FY | - JPY | 3.36% |
| 2018 Q1 | 51.45 Billion JPY | 86.77% |
| 2017 Q3 | 61.95 Billion JPY | 68.3% |
| 2017 FY | - JPY | -9.7% |
| 2017 Q4 | 27.54 Billion JPY | -55.54% |
| 2017 Q2 | 36.81 Billion JPY | -21.1% |
| 2017 Q1 | 46.66 Billion JPY | 166.82% |
| 2016 Q2 | 69.7 Billion JPY | 63.64% |
| 2016 Q4 | 17.48 Billion JPY | -79.06% |
| 2016 FY | - JPY | -18.83% |
| 2016 Q3 | 83.5 Billion JPY | 19.8% |
| 2016 Q1 | 42.59 Billion JPY | 2.46% |
| 2015 FY | - JPY | -12.94% |
| 2015 Q4 | 41.57 Billion JPY | -11.19% |
| 2015 Q3 | 46.8 Billion JPY | -28.44% |
| 2015 Q2 | 65.4 Billion JPY | 11.24% |
| 2015 Q1 | 58.79 Billion JPY | 0.0% |
| 2014 Q2 | 71.26 Billion JPY | 132.87% |
| 2014 Q1 | 30.6 Billion JPY | -62.72% |
| 2014 FY | - JPY | 17.2% |
| 2014 Q3 | 80.39 Billion JPY | 12.82% |
| 2013 Q1 | 59.49 Billion JPY | 219.05% |
| 2013 Q2 | 58.24 Billion JPY | -2.09% |
| 2013 Q4 | 82.08 Billion JPY | 24.11% |
| 2013 Q3 | 66.14 Billion JPY | 13.56% |
| 2013 FY | - JPY | -37.05% |
| 2012 Q4 | -49.97 Billion JPY | -150.46% |
| 2012 FY | - JPY | 9.42% |
| 2012 Q3 | 99.03 Billion JPY | 2.7% |
| 2012 Q2 | 96.43 Billion JPY | 49.64% |
| 2012 Q1 | 64.44 Billion JPY | -31.5% |
| 2011 Q3 | 87.36 Billion JPY | -4.15% |
| 2011 Q4 | 94.06 Billion JPY | 7.67% |
| 2011 Q2 | 91.15 Billion JPY | 38.36% |
| 2011 Q1 | 65.88 Billion JPY | -21.58% |
| 2011 FY | - JPY | 3.78% |
| 2010 Q4 | 84.01 Billion JPY | -10.22% |
| 2010 Q1 | 56.51 Billion JPY | -35.25% |
| 2010 Q2 | 91.81 Billion JPY | 62.46% |
| 2010 Q3 | 93.57 Billion JPY | 1.91% |
| 2010 FY | - JPY | 13.32% |
| 2009 Q2 | 83.83 Billion JPY | 0.0% |
| 2009 Q4 | 87.27 Billion JPY | -9.15% |
| 2009 Q3 | 96.06 Billion JPY | 14.59% |
| 2009 FY | - JPY | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| AstraZeneca PLC | 13.28 Billion USD | -1758.251% |
| Bristol-Myers Squibb Company PFD CONV 2 | 19.41 Billion USD | -1171.849% |
| CSPC Pharmaceutical Group Limited | 1.14 Billion USD | -21410.539% |
| Clarus Therapeutics Holdings, Inc. | -39.7 Million USD | 622074.562% |
| Novartis AG | 19.51 Billion USD | -1165.279% |
| PT Kalbe Farma Tbk. | 288.13 Million USD | -85608.48% |